

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5414791

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
DANIEL SUTHERLIN	07/10/2018
STEVEN MCKERRALL	07/10/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GENENTECH, INC.
<b>Street Address:</b>	1 DNA WAY
<b>City:</b>	SOUTH SAN FRANCISCO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94080-4990
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	CN2018077189
<b>Application Number:</b>	16283451
<b>PCT Number:</b>	US2019019266
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	650-225-2497
<b>Email:</b>	nikkin@gene.com
<b>Correspondent Name:</b>	NIKKI NOMURA
<b>Address Line 1:</b>	1 DNA WAY, MS-49
<b>Address Line 2:</b>	C/O GENENTECH, INC.
<b>Address Line 4:</b>	SOUTH SAN FRANCISCO, CALIFORNIA 94080
<b>ATTORNEY DOCKET NUMBER:</b>	P34653-WO/WO-1/US
<b>NAME OF SUBMITTER:</b>	NIKKI NOMURA
<b>SIGNATURE:</b>	/Nikki NOMURA/
<b>DATE SIGNED:</b>	03/11/2019
<b>Total Attachments: 10</b>	
source=P34653 - Assignment I-A from GNE inventors to GNE#page1.tif	
source=P34653 - Assignment I-A from GNE inventors to GNE#page2.tif	

source=P34653 - Assignment I-A from GNE inventors to GNE#page3.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page4.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page5.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page6.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page7.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page8.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page9.tif  
source=P34653 - Assignment I-A from GNE inventors to GNE#page10.tif

**CONFIRMATORY ASSIGNMENT**

WHEREAS, Daniel SUTHERLIN \_\_\_\_\_ ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of **10 July 2018**, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:

  
\_\_\_\_\_  
Daniel SUTHERLIN  
Mailing address:  
1 DNA Way  
South San Francisco, CA 94080  
Citizenship: US

  
\_\_\_\_\_  
GENENTECH, INC. *MDK*  
Name: Mark D. Kafka  
Assistant General Counsel  
Genentech, Inc.  
Title: Authorized Corporate Signatory

**EXHIBIT A TO CONFIRMATORY ASSIGNMENT\***

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
<b>P34653-WO</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>PCT/CN2018/077189</b>	<b>26 February 2018</b>

\*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

**UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>

**UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
P34653-WO	THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF	PCT/CN2018/077189	26 February 2018
P34653-AR	THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF	P190100443	22 February 2019
P34653-GC	THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF	2019/37087	22 February 2019
P34653-TW	THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF	108106002	22 February 2019
P34653-US	THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF	16/283451	22 February 2019
P34653-WO-1	THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF	PCT/US2019/019266	22 February 2019

**CONFIRMATORY ASSIGNMENT**

WHEREAS, Steven MCKERRALL ("ASSIGNOR"), has invented new and useful invention(s) as set forth in the applications listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, United States of America, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, United States of America, ("GENENTECH"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor, or, if ASSIGNOR has not assigned his or her interest in the INVENTION to GENENTECH pursuant to a prior agreement with GENENTECH, acquiring an interest in and to the INVENTION, and in and to the applications and patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR confirms that prior to, and no later than the earliest filing date of the applications listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNOR had assigned to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which that application claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

To the extent that ASSIGNOR has not already assigned all of his or her rights, title and interest in the INVENTION to GENENTECH via a prior agreement with GENENTECH, then for good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNOR does hereby assign to GENENTECH, any and all of his/her right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.


The ASSIGNOR agrees and authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR. ASSIGNOR agrees and acknowledges that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.



The terms and covenants of this Confirmatory Assignment shall inure to the benefit of GENENTECH, its successors, assigns or delegates, and shall be binding upon the ASSIGNOR, his or her respective heirs, successors and assigns.

This Confirmatory Assignment shall be governed by the substantial laws of California (excluding its conflicts of law principles).

IN WITNESS WHEREOF on this date of **10 July 2018**, the ASSIGNOR and GENENTECH have executed this Confirmatory Assignment and accepted the terms thereof:

  
\_\_\_\_\_

Steven MCKERRALL

Mailing address:

1 DNA Way

South San Francisco, CA 94080

Citizenship: US

  
\_\_\_\_\_  
GENENTECH, INC. *MDK*

Name: Mark D. Kafka  
Assistant General Counsel

Title: Genentech, Inc.  
Authorized Corporate Signatory

**EXHIBIT A TO CONFIRMATORY ASSIGNMENT\***

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
<b>P34653-WO</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>PCT/CN2018/077189</b>	<b>26 February 2018</b>

\*As agreed in this Confirmatory Assignment, ASSIGNOR hereby authorizes GENENTECH, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by GENENTECH, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNOR.

**UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>

## UPDATED EXHIBIT A TO CONFIRMATORY ASSIGNMENT

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
<b>P34653-WO</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>PCT/CN2018/077189</b>	<b>26 February 2018</b>
<b>P34653-AR</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>P190100443</b>	<b>22 February 2019</b>
<b>P34653-GC</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>2019/37087</b>	<b>22 February 2019</b>
<b>P34653-TW</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>108106002</b>	<b>22 February 2019</b>
<b>P34653-US</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>16/283451</b>	<b>22 February 2019</b>
<b>P34653-WO-1</b>	<b>THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF</b>	<b>PCT/US2019/019266</b>	<b>22 February 2019</b>